Tempus Partners with Moderna and Merck for Cancer Therapy Commercialization

Key Facts

Tempus announced a multi-year collaboration with Moderna and Merck to support the potential commercialization of intismeran autogene. Business Wire reported that the partnership aims to facilitate the clinical evaluation and future market entry of the V940/mRNA-4157 therapy, an individualized neoantigen treatment used in combination with Keytruda for melanoma and other cancer types.

MRNA closed at $187.46 on October 6, 2026, while MRK closed at $141.93 on the same date. This strategic expansion focuses on the long-term commercial pipeline for first-in-class therapies involving these major pharmaceutical partners.